SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Roche breast cancer pill cuts risk of disease recurrence by 30% in trial - 2Nordic people know how to beat the winter blues. Here's how to find light in the darkest months
- 3Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy
- 4Make your choice for a definitive Christmas place to get-away!
- 5Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- Black Friday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60%
- November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
- Trial of pro-Palestine activist begins
- 7 Straightforward Moves toward Move Information from Your Old Cell phone to Your New One: A Thorough Aide
- Your big brain makes you human – count your neurons when you count your blessings
- Most loved Occasion Dish: What Makes Your Merry Table?
- Figure out how to Arrange a Fair Settlement with the Assistance of a Fender bender Legal counselor
